JP2017530195A5 - - Google Patents

Download PDF

Info

Publication number
JP2017530195A5
JP2017530195A5 JP2017536991A JP2017536991A JP2017530195A5 JP 2017530195 A5 JP2017530195 A5 JP 2017530195A5 JP 2017536991 A JP2017536991 A JP 2017536991A JP 2017536991 A JP2017536991 A JP 2017536991A JP 2017530195 A5 JP2017530195 A5 JP 2017530195A5
Authority
JP
Japan
Prior art keywords
rivastigmine
formulation
aqueous
nasal
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017536991A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017530195A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2015/050591 external-priority patent/WO2016049700A1/en
Publication of JP2017530195A publication Critical patent/JP2017530195A/ja
Publication of JP2017530195A5 publication Critical patent/JP2017530195A5/ja
Priority to JP2020036966A priority Critical patent/JP7357571B2/ja
Pending legal-status Critical Current

Links

JP2017536991A 2014-10-03 2015-09-30 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物 Pending JP2017530195A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020036966A JP7357571B2 (ja) 2014-10-03 2020-03-04 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014903944A AU2014903944A0 (en) 2014-10-03 Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders
AU2014903944 2014-10-03
PCT/AU2015/050591 WO2016049700A1 (en) 2014-10-03 2015-09-30 Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020036966A Division JP7357571B2 (ja) 2014-10-03 2020-03-04 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物

Publications (2)

Publication Number Publication Date
JP2017530195A JP2017530195A (ja) 2017-10-12
JP2017530195A5 true JP2017530195A5 (enExample) 2018-11-08

Family

ID=55629161

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017536991A Pending JP2017530195A (ja) 2014-10-03 2015-09-30 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物
JP2020036966A Active JP7357571B2 (ja) 2014-10-03 2020-03-04 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物
JP2021171712A Pending JP2022003100A (ja) 2014-10-03 2021-10-20 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020036966A Active JP7357571B2 (ja) 2014-10-03 2020-03-04 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物
JP2021171712A Pending JP2022003100A (ja) 2014-10-03 2021-10-20 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物

Country Status (12)

Country Link
US (3) US10471040B2 (enExample)
EP (1) EP3200828B1 (enExample)
JP (3) JP2017530195A (enExample)
AU (1) AU2015327762C1 (enExample)
CA (1) CA2961936C (enExample)
DK (1) DK3200828T3 (enExample)
ES (1) ES2822562T3 (enExample)
HU (1) HUE052441T2 (enExample)
PL (1) PL3200828T3 (enExample)
PT (1) PT3200828T (enExample)
SM (1) SMT202000576T1 (enExample)
WO (1) WO2016049700A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202000576T1 (it) * 2014-10-03 2020-11-10 Lachesis Biosciences Ltd Composizioni intranasali per il trattamento di malattie e disturbi neurologici e neurodegenerativi
AR111699A1 (es) * 2017-02-02 2019-08-14 Otolanum Ag Composición farmacéutica que comprende betahistina
WO2021258150A1 (en) * 2020-06-25 2021-12-30 Lachesis Biosciences Limited Methods of treating or preventing organophosphorus poisoning
EP4221645A4 (en) * 2020-10-01 2024-10-02 Lyra Therapeutics, Inc. Osmotic drug delivery implants
CN115919767B (zh) * 2022-10-13 2023-08-11 暨南大学 卡巴拉汀鼻喷雾剂及其制备方法
CN119523898A (zh) * 2024-12-02 2025-02-28 肇庆学院 多靶点药物的经鼻给药制剂及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5733M (enExample) 1966-09-27 1968-01-22
US4806543A (en) 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
FR2722989B1 (fr) 1994-07-29 1997-05-30 Synthelabo Utilisation de l'ifenprodil et de ses enantiomeres pour la preparation de medicaments utiles dans le traitement des neuropathies peripheriques et des maladies neurodegeneratives centrales
US6558560B2 (en) * 2001-07-27 2003-05-06 Hewlett-Packard Company Method for the fabrication of electrical contacts
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20040254146A1 (en) * 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
US20030225031A1 (en) * 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
DE602005010899D1 (de) * 2004-09-27 2008-12-18 Sigmoid Pharma Ltd Mikrokapseln mit einem methylxanthin und einem kortikosteroid
US8187570B1 (en) * 2005-01-04 2012-05-29 Gp Medical, Inc. Nanoparticles for protein drug delivery
BRPI0607017B8 (pt) * 2005-04-06 2021-05-25 Adamas Pharmaceuticals Inc composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
EP1933809B1 (en) * 2005-10-11 2012-02-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
KR20080097443A (ko) * 2006-02-03 2008-11-05 아바니르 파마슈티컬스 덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물
EP1981475A2 (en) * 2006-02-09 2008-10-22 Schering Corporation Pharmaceutical formulations
EP2172224A4 (en) * 2007-06-26 2013-01-16 Wakamoto Pharma Co Ltd AQUEOUS COMPOSITION
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
CN103221411B (zh) 2010-05-17 2016-05-11 富瑞姆制药公司 (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型
US8673338B2 (en) * 2011-07-29 2014-03-18 Massachusetts Eye And Ear Infirmary Methods of delivering pharmaceutical agents
SMT202000576T1 (it) * 2014-10-03 2020-11-10 Lachesis Biosciences Ltd Composizioni intranasali per il trattamento di malattie e disturbi neurologici e neurodegenerativi

Similar Documents

Publication Publication Date Title
JP2017530195A5 (enExample)
JP6657454B2 (ja) ブプレノルフィンの乱用抵抗性粘膜付着性送達デバイス
US11872314B2 (en) Pharmaceutical compositions
US20210308040A1 (en) Ketamine oral transmucosal delivery system
JP2018517676A5 (enExample)
JP2016512833A (ja) ウイルス感染症の治療薬としてのベラプロスト異性体
TW201016209A (en) Intranasal compositions, dosage forms and methods of treatments
WO2013081565A1 (en) Pharmaceutical compositions comprising roflumilast and terbutaline
JP5775970B2 (ja) 口腔貼付剤
JP2008518007A5 (enExample)
RU2007119721A (ru) Частицы для лечения легочной инфекции
JP2014521641A5 (enExample)
JP2023545372A (ja) デクスメデトミジン塩酸塩を用いた双極性障害及び精神病の治療
CA3127926A1 (en) Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
JP2016502991A5 (enExample)
JP2013253038A (ja) 口腔内溶解型フィルム製剤
WO2010023874A1 (ja) ロペラミド塩酸塩含有フィルム製剤
KR20190009294A (ko) 비강 울혈을 치료/예방하기 위한 카르복실산
CN108024952A (zh) 在治疗发作中用于口颊施用以获得快速起效的咪达唑仑组合物
JP2014525891A5 (enExample)
JP5819680B2 (ja) 塩酸アンブロキソールの小型徐放性製剤
Rajab et al. Influence of tamarind seed gum derivatives on the in vitro performance of gastro-retentive tablets based on hydroxypropylmethylcellulose
JP2018111691A (ja) 眼科用水性組成物、及び化合物の含量低下を抑制する方法
CN114585364A (zh) 谷氨酸2b受体拮抗剂和σ受体激动剂作为止咳药的用途
CN111971034A (zh) 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用